Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 02:15PM GMT
Release Date Price: €60.8 (+2.12%)
Tazeen Ahmad
BofA Securities, Research Division - VP

Good morning, everybody. Thanks for joining us again for the next segment of our Bank of America Healthcare Conference. It's my pleasure to introduce our next presenting company, Sage Therapeutics. Presenting for Sage with us for the next 30 minutes is CEO, Barry Greene. Barry, Good morning. Thank you for joining us.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Good morning, Tazeen, and thanks for having us at the conference today. Appreciate it.

Tazeen Ahmad
BofA Securities, Research Division - VP

So there's a lot to talk about. I don't think we're going to get through everything in 30 minutes, but we're going to try to speed through some of the important things.

Questions & Answers

Tazeen Ahmad
BofA Securities, Research Division - VP

So for anybody who is not familiar with Sage, maybe talk to us about the company for a minute about kind of what the overall arching goal of Sage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot